Ross operation with a tissue-engineered heart valve
Ross operation with a tissue-engineered heart valve
复制标题
DOI：
10.1016/s0003-4975(02)03881-x
复制
发表时间：
2002-11-01
影响因子：
4.6
通讯作者：
Konertz, WF
中科院分区：
文献类型：
--
作者：
Dohmen, PM;Lembcke, A;Konertz, WF
Background. The Ross procedure has gained increasing acceptance due to excellent hemodynamic results by replacing the diseased aortic valve with the viable autologous pulmonary valve. Consequently, the right ventricular outflow tract (RVOT) has to be reconstructed. In this report a viable heart valve was created from decellularized cryopreserved pulmonary allograft that was seeded with viable autologous vascular endothelial cells (AVEC).Methods. A 43-year-old patient suffering from aortic valve stenosis underwent a Ross operation on May 20, 2000, using a tissue engineered (TE) pulmonary allograft to reconstruct the RVOT. Four weeks before the operation a piece of forearm vein was harvested to separate, culture, and characterize AVEC. Follow-up was completed at discharge, 3, 6, and 12 months postoperatively by clinical evaluation, transthoracic echocardiography (TTE), and magnetic resonance imaging (MRI). Additionally, at 1-year follow-up a multislice computed tomographic scan was performed.Results. After four weeks of culturing 8.34 X 10(6) AVEC were available to seed a 27-mm decellularized pulmonary allograft. Trypan blue staining confirmed 96.0% viability. Reendothelialization rate after seeding was 9.0 X 10(5) cells/cm(2). TTE and MRI revealed excellent hemodynamic function of the TE heart valve and the neoaortic valve as well. Multislice computed tomography revealed no evidence of valvular calcification.Conclusions. After 1 year of follow-up the patient is in excellent condition without limitation and exhibits normal aortic and pulmonary valve function.
